Jonathan Hunt detailed the investment strategy of Syngene International, facing revenue growth challenges due to US biotech funding delays. Expecting high single to low double digits growth for FY25, with ongoing developments in various company facilities. Hunt says: “We deployed $55 million last year. Next year, we will be a little bit ahead of that.”
| Subscribe To Our Free Newsletter |
